 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 December 2001 | Volume 135 Issue 12 | Pages 1074-1078
Several recent comparative trials in hypertension have reported that similar blood pressure reductions may not necessarily translate into similar reductions in risk for cardiovascular complications. Thus, the method used to lower blood pressure may be important. In the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT), low-dose chlorthalidone as the first-line drug was superior to doxazosin. The 25% higher risk for major cardiovascular events associated with doxazosin was attributed primarily to a doubling in the risk for heart failure. A meta-analysis of patients with type 2 diabetes mellitus suggested that despite achieving similar blood pressure reductions, angiotensin-converting enzyme inhibitors are superior to other antihypertensive drugs in reducing the risk for acute myocardial infarction and cardiovascular events, but not stroke. Although individual comparative trials have failed to show conclusively that calcium-channel blockers differ from other antihypertensive drugs, a meta-analysis that included all published trials concluded that calcium-channel blockers are inferior to other classes of drugs in reducing the risk for acute myocardial infarction and heart failure.
These observations suggest not only that antihypertensive drugs may have important mechanisms of action apart from blood pressure lowering but also that effective treatment is not a matter of simply lowering blood pressure. These findings have potential implications for the regulatory approval of antihypertensive agents, revisions of treatment guidelines, the design of future randomized trials comparing different antihypertensive drugs and, most important, the selection of drugs for the treatment of hypertensive patients.
Author and Article Information
From Wake Forest University School of Medicine, Winston-Salem, North Carolina; University of Washington, Seattle, Washington; and Albert Einstein College of Medicine, Bronx, New York.
Requests for Single Reprints: Curt D. Furberg, MD, PhD, Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1063; e-mail, cfurberg{at}wfubmc.edu.
Current Author Addresses: Dr. Furberg: Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1063.
Dr. Psaty: Cardiovascular Health Research Unit, Metropolitan Park, East Tower, 1730 Minor Avenue, Suite 1360, Seattle, WA 98101.
Dr. Pahor: Department of Internal Medicine, Section on Geriatrics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1207.
Dr. Alderman: Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. PERSPECTIVE
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  N. Chapman, C. L. Chang, B. Dahlof, P. S. Sever, H. Wedel, N. R. Poulter, and on behalf of the ASCOT Investigators Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial Circulation, July 1, 2008; 118(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma and R. S. Stafford Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003-2004 Hypertension, May 1, 2008; 51(5): 1275 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Yank, D. Rennie, and L. A Bero Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study BMJ, December 8, 2007; 335(7631): 1202 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Stafford, V. Monti, C. D. Furberg, and J. Ma Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States Hypertension, August 1, 2006; 48(2): 213 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Diuretic Versus {alpha}-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension, September 1, 2003; 42(3): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Schlaich, D. M. Kaye, E. Lambert, M. Sommerville, F. Socratous, and M. D. Esler Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy Circulation, August 5, 2003; 108(5): 560 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Nusbaum Commentary: Making "Me-too" Drugs Benefit the Public American Journal of Medical Quality, November 1, 2002; 17(6): 215 - 217. [Abstract] [PDF]
|
|
|
|
 |
|
 R A Deyo Bruce Psaty and the risks of calcium channel blockers Qual. Saf. Health Care, September 1, 2002; 11(3): 294 - 296. [Full Text] [PDF]
|
|
|
|
 |
|
 C. D Furberg To whom do the research findings apply? Heart, June 1, 2002; 87(6): 570 - 574. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mulrow Sound Clinical Advice for Hypertensive Patients Ann Intern Med, December 18, 2001; 135(12): 1084 - 1086. [Full Text] [PDF]
|
|
Article
